Spero Therapeutics (NASDAQ:SPRO) Insider Esther Rajavelu Sells 87,917 Shares of Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the sale, the insider owned 1,012,091 shares in the company, valued at $2,388,534.76. This represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Esther Rajavelu also recently made the following trade(s):

• On Monday, February 2nd, Esther Rajavelu sold 18,442 shares of Spero Therapeutics stock. The shares were sold at an average price of $2.20, for a total transaction of $40,572.40.

Spero Therapeutics Price Performance

Shares of SPRO stock opened at $2.36 on Tuesday. Spero Therapeutics, Inc. has a 12 month low of $0.51 and a 12 month high of $3.22. The firm has a market capitalization of $132.96 million, a P/E ratio of -2.99 and a beta of 1.45. The company’s fifty day moving average price is $2.35 and its two-hundred day moving average price is $2.24.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.12. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%.The company had revenue of $5.44 million during the quarter, compared to the consensus estimate of $12.00 million. On average, sell-side analysts anticipate that Spero Therapeutics, Inc. will post -1.2 EPS for the current year.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SPRO. Ionic Capital Management LLC boosted its holdings in Spero Therapeutics by 39.2% in the third quarter. Ionic Capital Management LLC now owns 208,725 shares of the company’s stock worth $392,000 after purchasing an additional 58,725 shares during the period. Shay Capital LLC acquired a new position in shares of Spero Therapeutics in the 3rd quarter valued at about $120,000. Two Sigma Investments LP acquired a new position in shares of Spero Therapeutics in the 3rd quarter valued at about $93,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Spero Therapeutics during the 3rd quarter valued at about $283,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Spero Therapeutics during the third quarter worth about $55,000. 25.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on SPRO. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, January 11th. Zacks Research lowered shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce”.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.